Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XL Antineoplastic cell and gene therapy
L01XL04 Tisagenlecleucel
D11386 Tisagenlecleucel-T (USAN) <US>
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD19
D11386 Tisagenlecleucel-T (USAN) <US>
New drug approvals in the USA [br08319.html]
Cellular and gene therapy products
D11386
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11386
Cellular and gene therapy products
D11386
New drug approvals in Japan [br08318.html]
Cellular and gene therapy products
D11386
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11386
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11386
